Show summary Hide summary
Dave Coulier, known for his role on Full House, told Good Morning America this week that he is now in remission after treatment for two separate cancers — a recent tongue tumor found during follow-up care for an earlier lymphoma diagnosis. His update underscores the importance of routine scans and quick action after suspicious findings.
From lymphoma to tongue cancer: a swift, unexpected turn
In November 2024 Coulier publicly disclosed a diagnosis of stage 3 non-Hodgkin lymphoma. During a subsequent checkup, a PET scan flagged an abnormality in his throat. Doctors performed a robotic-assisted procedure that removed part of his tongue for biopsy, which led to a second diagnosis: p16 squamous carcinoma at the base of the tongue.
Mira Sorvino brings star power to Woodstock after Broadway triumph
Tiki Ghosn rocks streamer DeenTheGreat during live party after disrespect
The two cancers are unrelated, Coulier said, and after surgery and follow-up treatment he now reports both illnesses are in remission. He described the tongue operation as painful and invasive, and has been candid about the emotional and physical toll of back-to-back cancer care.
Support system and small moments that mattered
Coulier credited his wife, Melissa Bring, and friends from his Full House circle for steadying him. He recounted a visit from John Stamos — a brief, lighthearted interlude that helped break the tension — and even joked about sharing an awkward bout of COVID while Stamos stayed with them, which turned into an unexpectedly silly memory.
- Diagnosis timeline: Stage 3 non-Hodgkin lymphoma announced Nov. 2024; tongue carcinoma identified during a later PET scan.
- Treatment steps: Robotic surgery to remove part of the tongue for biopsy, followed by appropriate oncological care.
- Current status: Coulier says both cancers are in remission.
- Takeaway: He urges people to prioritize routine exams and screenings — from prostate checks to mammograms — because early detection can be decisive.
Coulier told the program he never wanted to be a “poster boy” for cancer awareness, but he hopes sharing his experience motivates others to see a physician sooner rather than later. He emphasized that even in remission, the experience leaves a lasting impression — cancer, he says, remains “in the rear-view mirror.”
Why this matters now: Coulier’s case is a reminder that follow-up imaging after cancer treatment can reveal unrelated health issues, and that prompt investigation of new findings can change outcomes. For readers, the practical consequence is clear — stay current with recommended screenings and speak up about unusual symptoms.
